Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment.
We investigated the effects of hepatic and renal impairment on the pharmacokinetics of enrofloxacin in Sprague-Dawley rats. Experimental hepatic and renal failure were induced by carbon tetrachloride (CCL(4)) and 5/6 nephrectomy, respectively. After intravenous dosing of enrofloxacin (10 mg/kg), plasma concentrations of enrofloxacin were measured using liquid chromatograph/mass spectrometry. There was no significant effect of hepatic impairment on enrofloxacin pharmacokinetics. However, renal impairment markedly prolonged elimination half life (t(1/2lambdaz)) of enrofloxacin (P < 0.05), comparing with respective control. Total body clearance (Cl(b)) and volume of distribution at steady state (V(ss)) were significantly decreased (P < 0.05) by renal impairment. In conclusion, these results suggested that renal impairment could affect the pharmacokinetics of enrofloxacin.
Hwang
Y H
YH
Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University, Yuseong-gu, Daejeon 305-764, Republic of Korea. hiyun@cnu.ac.kr
Kim
M S
MS
Song
I B
IB
Lim
J H
JH
Park
B K
BK
Yun
H I
HI
D000818:Animals; D000970:Antineoplastic Agents / Q000097:blood / Q000493:pharmacokinetics*; D002252:Carbon Tetrachloride Poisoning / Q000473:pathology; D000077422:Enrofloxacin; D024841:Fluoroquinolones / Q000097:blood / Q000493:pharmacokinetics*; D017093:Liver Failure / Q000139:chemically induced*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D051437:Renal Insufficiency / Q000139:chemically induced*
D000970:Antineoplastic Agents; D024841:Fluoroquinolones; D000077422:Enrofloxacin